Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine
Royals C Salvador Perez scratched from game against Blue Jays because of tight back
Analysis: Larson enters conversation with Verstappen as best drivers in the world
Dead infant found at Florida university campus; police investigating
Patriots' Christian Barmore agrees to 4
Politicians, dog experts vilify South Dakota Gov. Kristi Noem for killing her dog
Supreme Court rejects an appeal from a Canadian man once held at Guantanamo
Messi to Miami: Soccer star, and a few teammates, show up for Heat
Yvette Fielding says her Most Haunted co
Sea off New England had one of its hottest years in 2023, part of a worldwide trend